NEW YORK (360Dx) – Qiagen said this week that it has joined Cancer-ID, a public-private consortium that aims to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.

With 36 partners from 13 countries, the Cancer-ID consortium is a project of the Innovative Medicines Initiative, a European public-private program that aims to speed up the development of better and safer medicines for patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.